This ''Borderline Personality Disorders - Pipeline Insight, 2022,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Borderline Personality Disorders pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
The term ‘Borderline Personality Disorder' (BPD) refers to a psychiatric syndrome that is characterized by emotion dysregulation, impulsivity, risk-taking behavior, irritability, feelings of emptiness, self-injury and fear of abandonment, as well as unstable interpersonal relationships. Paranoid ideation and dissociative states are also transient features of the syndrome. Moreover, many patients with BPD show recurring self-injurious or suicidal behavior. BPD has a lifetime prevalence of about 6%. It is much more common in clinical settings, thus rendering BPD highly relevant for health care providers and public health in general.
BPD is often a comorbid condition of other psychiatric disorders (formerly conceptualized as axis-I disorders according to DSM-IV), foremost depression, other personality disorders, and there seems to be syndromal overlap and/or comorbidity with bipolar disorder (BD), attention deficit/hyperactivity disorder (ADHD) and posttraumatic stress disorder (PTSD).
"Borderline Personality Disorders - Pipeline Insight, 2022" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Borderline Personality Disorders pipeline landscape is provided which includes the disease overview and Borderline Personality Disorders treatment guidelines. The assessment part of the report embraces, in depth Borderline Personality Disorders commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Borderline Personality Disorders collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Vafidemstat: Oryzon
Vafidemstat (ORY-2001) is an oral small molecule that has been optimized for CNS indications and that acts as a covalent inhibitor of the epigenetic enzyme Lysine Specific Demethylase-1, LSD1 (KDM1A). Oryzon has performed a Phase IIa clinical trial (REIMAGINE study) to assess vafidemstat's effects on agitation-aggression in patients with different psychiatric disorders: Autism Spectrum Disorder (ASD), Borderline Personality Disorder (BPD) and adult Attention Deficit Hyperactivity Disorder (ADHD).
This segment of the report provides insights about the Borderline Personality Disorders drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 5+ key companies which are developing the therapies Borderline Personality Disorders. The companies which have their Borderline Personality Disorders drug candidates in the most advanced stage, i.e Phase II include Oryzon
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Borderline Personality Disorders therapeutic drugs key players involved in developing key drugs.
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Borderline Personality Disorders drugs.
This product will be delivered within 2 business days.
Geography Covered
- Global coverage
Borderline Personality Disorders Understanding
The term ‘Borderline Personality Disorder' (BPD) refers to a psychiatric syndrome that is characterized by emotion dysregulation, impulsivity, risk-taking behavior, irritability, feelings of emptiness, self-injury and fear of abandonment, as well as unstable interpersonal relationships. Paranoid ideation and dissociative states are also transient features of the syndrome. Moreover, many patients with BPD show recurring self-injurious or suicidal behavior. BPD has a lifetime prevalence of about 6%. It is much more common in clinical settings, thus rendering BPD highly relevant for health care providers and public health in general.
BPD is often a comorbid condition of other psychiatric disorders (formerly conceptualized as axis-I disorders according to DSM-IV), foremost depression, other personality disorders, and there seems to be syndromal overlap and/or comorbidity with bipolar disorder (BD), attention deficit/hyperactivity disorder (ADHD) and posttraumatic stress disorder (PTSD).
"Borderline Personality Disorders - Pipeline Insight, 2022" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Borderline Personality Disorders pipeline landscape is provided which includes the disease overview and Borderline Personality Disorders treatment guidelines. The assessment part of the report embraces, in depth Borderline Personality Disorders commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Borderline Personality Disorders collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence R&D Borderline Personality Disorders. The therapies under development are focused on novel approaches to treat/improve Borderline Personality Disorders.
Borderline Personality Disorders Emerging Drugs
Vafidemstat: Oryzon
Vafidemstat (ORY-2001) is an oral small molecule that has been optimized for CNS indications and that acts as a covalent inhibitor of the epigenetic enzyme Lysine Specific Demethylase-1, LSD1 (KDM1A). Oryzon has performed a Phase IIa clinical trial (REIMAGINE study) to assess vafidemstat's effects on agitation-aggression in patients with different psychiatric disorders: Autism Spectrum Disorder (ASD), Borderline Personality Disorder (BPD) and adult Attention Deficit Hyperactivity Disorder (ADHD).
Borderline Personality Disorders: Therapeutic Assessment
This segment of the report provides insights about the Borderline Personality Disorders drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Borderline Personality Disorders
There are approx. 5+ key companies which are developing the therapies Borderline Personality Disorders. The companies which have their Borderline Personality Disorders drug candidates in the most advanced stage, i.e Phase II include Oryzon
Phases
This report covers around 5+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Borderline Personality Disorders pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Intravenous
- Subcutaneous
- Molecule Type
Products have been categorized under various Molecule types such as
- Small molecule
- Cell Therapy
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Borderline Personality Disorders: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Borderline Personality Disorders therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Borderline Personality Disorders drugs.
Borderline Personality Disorders Report Insights
- Borderline Personality Disorders Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Borderline Personality Disorders Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Borderline Personality Disorders drugs?
- How many Borderline Personality Disorders drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Borderline Personality Disorders?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Borderline Personality Disorders therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Borderline Personality Disorders and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Oryzon
- Boehringer Ingelheim
- Otsuka
- Intra-Cellular Therapies
Key Products
- Vafidemstat
- BI1358894
- Brexpiprazole
- Caplyta
- Rexulti
This product will be delivered within 2 business days.
Table of Contents
IntroductionExecutive Summary
Borderline Personality Disorders: Overview
- What is Borderline Personality Disorders?
- Types of Borderline Personality Disorders
- Causes
- Epidemiology and Risk Factors
- Disease Management
- Comparative Analysis
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
- Comparative Analysis
- Product Description
- Research and Development
- Product Development Activities
- Comparative Analysis
- Product Description
- Research and Development
- Product Development Activities
Caplyta: Otsuka
- Product Description
- Research and Development
- Product Development Activities
- Comparative Analysis
- Product Description
- Research and Development
- Product Development Activities
- Comparative Analysis
Borderline Personality Disorders Key Products
Borderline Personality Disorders- Unmet Needs
Borderline Personality Disorders- Market Drivers and Barriers
Borderline Personality Disorders- Future Perspectives and Conclusion
Borderline Personality Disorders Analyst Views
Borderline Personality Disorders Key Companies
AppendixList of Tables
Table 1 Total Products for Borderline Personality Disorders
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive ProductsList of Figures
Figure 1 Total Products for Borderline Personality Disorders
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Companies Mentioned
A selection of companies mentioned in this report includes:
- Oryzon
- Boehringer Ingelheim
- Otsuka
- Intra-Cellular Therapies
